TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02483611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisatracurium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Study: NCT02837549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy treatment
Description: This intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education
Study: NCT01740765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-hour energy expenditure
Description: To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-hour energy expenditure
Description: To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-hour energy expenditure
Description: To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
Study: NCT02422641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Methotrexate (8 gm/m2; HD-MTX)
Description: Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
Study: NCT03145064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered at a dose of 160 mg BID orally.
Study: NCT01323933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB0024
Description: Comparison of different dosages of drug
Study: NCT03262285

Intervention type: PROCEDURE
Intervention: phacoemulsification
Description: removal of cataract using ultrasound waves

Intervention type: PROCEDURE
Intervention: extracapsular cataract extraction
Description: removal of cataract using surgical corneal incision
Study: NCT03381703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852
Description: YH12852 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852
Description: YH12852 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled YH12852
Description: 14C-labeled YH12852 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled YH12852
Description: 14C-labeled YH12852 administration
Study: NCT00861302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body emotional awareness program
Description: This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
Study: NCT01960179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixisenatide AVE0010
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection
Study: NCT02254304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif
Description: Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif
Description: Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
Study: NCT03030157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirarubicin(THP)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pirarubicin(THP)
Study: NCT03040518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative SMS
Description: Narrative SMS have been defined as interactive life stories based around a range of characters (varying in age and socio-demographics) which can simulate the processes that make group-based interventions successful: humour, banter, peer support, facts about diet and PA and evidence based BCTs. The narrative form draws on real world learning from the film, television and games industry. When theorised, the narrative enables engagement with characters who convey the message of the intervention, and facilitate the viewer's empathy. Through creating an empathic bond with the character, users pay more attention to and become engaged and immersed within the story. This appears to lead to optimal learning and conceptualisation of the target information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative SMS
Description: Narrative SMS have been defined as interactive life stories based around a range of characters (varying in age and socio-demographics) which can simulate the processes that make group-based interventions successful: humour, banter, peer support, facts about diet and PA and evidence based BCTs. The narrative form draws on real world learning from the film, television and games industry. When theorised, the narrative enables engagement with characters who convey the message of the intervention, and facilitate the viewer's empathy. Through creating an empathic bond with the character, users pay more attention to and become engaged and immersed within the story. This appears to lead to optimal learning and conceptualisation of the target information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endowment Incentive
Description: All participants will be 'endowed' with an incentive at the start of the trial. It will be placed into a hypothetical personal account which is theirs for a year (no withdrawals). Participants will be able to secure money for verified weight loss at 3, 6, and 12 months.
Study: NCT02516995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study: NCT04438759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncomfort, commercially available Virtual Reality headset
Description: Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform 93/42/EEC and 2007/47/EEC
Study: NCT02902692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness
Description: 15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
Study: NCT03591198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong Training
Description: Eight-Section Brocades

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
Study: NCT02363673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised homoeopathic remedy in aqua distilla
Description: Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
Study: NCT02254993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide
Study: NCT01630824

Intervention type: OTHER
Group type: OTHER
Intervention: Structured education program
Description: structured education program after kidney transplantation
Study: NCT02254759

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam, IV
Description: 2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, IV
Description: 2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam, oral
Description: 0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, oral
Description: 0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5186582
Description: RO5186582 120 mg film-coated release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5186582
Description: RO5186582 120 mg film-coated release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5186582
Description: RO5186582 120 mg film-coated release tablet.
Study: NCT02999763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SlimShape
Description: SlimShape radiofrequency treatment to the abdomen
Study: NCT04428710

Intervention type: OTHER
Intervention: assessment with psychometric questionnaire
Description: At the initial genetic consultation patients are informed about hereditary cancer risk and the genetic testing process. At the second genetic counseling appointment, after patients done tests, all participants were informed about the study purpose, and they signed the informed consent before the psychometric assessment. Those patients who agreed to participate, they were given the questionnaires to fill in. Also, background characteristics were reported including age, marital relationship, level of education, psychiatric antecedents.~The time for completion the self-report measures was about 10 minutes. The psychometric assessment was occurred prior to delivering the results of genetic testing.
Study: NCT00817154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPES-I
Description: The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
Study: NCT01378416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (Dacogen)
Description: Intravenous injection; total dose-per-cycle was 135 mg/m\^2 of decitabine.
Study: NCT05063864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Support Program
Description: Within the scope of the nursing support program, counselling services were provided to women by making regular phone calls that lasted 15-20 minutes once a week. Within the scope of the support program, two training booklets titled Life After Hysterectomy Surgery and Women's Health During Menopause were prepared by reviewing the literature.
Study: NCT05075421

Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: Any type of gastrectomy for gastric cancer

Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: Any type of gastrectomy for gastric cancer
Study: NCT02139813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Mini-gastric bypass
Description: The laparoscopic Omega Loop Bypass will consist of:~* a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His~* a narrow gastric tube will be calibrated to be approximately 1.5 cm wide~* an Omega loop of 200 cm~* a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure of reference in bariatric surgery
Description: The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects
Study: NCT01009424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R7103
Description: escalating inhaled dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R7103
Description: escalating inhaled dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R7103
Description: escalating inhaled dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R7103
Description: escalating inhaled dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R7103
Description: escalating inhaled dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R7103
Description: escalating inhaled dose
Study: NCT02951585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KARTILAGE CROSS
Description: Intra-articular injection of Kartilage Cross
Study: NCT02254993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: antimicrobial peptide
Study: NCT02951585

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Intra-articular injection of physiological serum (saline solution)
Study: NCT02540655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stemchymal®
Description: Patients will receive Stemchymal® through intravenous infusion

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Excipients
Description: Patients will receive excipients through intravenous infusion
Study: NCT03836937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: Farnesoid X receptor ligand which is a semi synthetic bile acid analogue
Study: NCT02047890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1000394 (2.5mg)
Description: BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1000394 (5mg)
Description: BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
Study: NCT01288495

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplemental L-alanine
Description: Subjects will consume l-alanine prior to eating fructose-containing foods.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Metamucil
Description: Subjects will consume the placebo prior to eating fructose-containing foods.
Study: NCT03487276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1
Description: Single IV infusions of IFX-1 diluted in sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1
Description: Single IV infusions of IFX-1 diluted in sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1
Description: Single IV infusions of IFX-1 diluted in sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1
Description: Single IV infusions of IFX-1 diluted in sodium chloride.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01240720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-F16SIP Radioimmunotherapy (RIT)
Description: * Dosimetric evaluation with 131I-F16SIP or 124I-F16SIP will be performed to assess eligibility for Radioimmunotherapy.~* Patients eligible for Radioimmunotherapy will receive 55.5 mCi/m2 as established in the Phase I part of the study. A single dose of 5 to 10 mg of 131I-F16SIP will be administered intravenously (I.V).
Study: NCT01267734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting coronary stenting system (EECSS, Promus Element)
Description: Everolimus-eluting stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting coronary stenting system (EECSS, Promus Element)
Description: Everolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)
Description: Zotarolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)
Description: Zotarolimus-eluting stent
Study: NCT01499212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: I:E ratio
Description: I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
Study: NCT03482336

Intervention type: OTHER
Group type: OTHER
Intervention: Four FOP label designs
Description: Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a healthy level while the second unhealthy. Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables.
Study: NCT01267734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple anti-platelet therapy (TAT)
Description: 100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple anti-platelet therapy (TAT)
Description: 100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel anti-platelet therapy (DDAT)
Description: 100mg Aspirin QD + 150mg Clopidogrel QD for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double-dose clopidogrel anti-platelet therapy (DDAT)
Description: 100mg Aspirin QD + 150mg Clopidogrel QD for 1 month
Study: NCT01823523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin, Cephalexin, Clindamycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cefazolin, Cephalexin, Clindamycin
Study: NCT02115789

Intervention type: BEHAVIORAL
Intervention: Visual Analog Scale
Description: Subjects will review examples of both linear and zigzag scars and rate the aesthetic appearance of both configurations of scars on a scale of 1 through 10, with 1 being normal skin and 10 being the worst scar imaginable.
Study: NCT01682057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROX ANASTOMOTIC COUPLER SYSTEM (ACS)
Description: The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROX Anastomotic Coupler System (ACS)
Study: NCT02603614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenderitide
Description: Cenderitide is a dual receptor natriuretic peptide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenderitide
Description: Cenderitide is a dual receptor natriuretic peptide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control
Study: NCT05240053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enhanced recovery programe
Description: Early postoperative analgesia , early oral intake , early mobilization , early removal of nasogastric tube \& drains if any. The patients in this group started clear fluid once they awaked from anesthesia , a full liquid diet on first postoperative day , normal diet on second day provided that there was no vomiting or abdominal distension. The patients in this group were instructed for early ambulation \& encouraged to stay out of the bed for 4 hours on first day postoperative , 6 hours in following day , 8 hours on subsequent days. Also they were encouraged to walk the length of 3 meters once on first day postoperative , twice on day 2 \& three times on subsequent days. Regarding analgesia in this group postoperatively , they were received fentanyl via an epidural catheter.
Study: NCT02157467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho Cyclen
Study: NCT04079101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.